Yes, Ajovy (fremanezumab-vfrm) is a biologic medication. It was approved by the FDA in 2018 through a Biologics License Application, which is the regulatory pathway reserved specifically for biologic drugs. Ajovy is classified as a fully humanized monoclonal antibody, a type of biologic engineered to target and block a specific protein involved in migraine attacks.
What Makes Ajovy a Biologic
The distinction between a biologic and a traditional drug comes down to how it’s made. Conventional medications are synthesized through chemical processes, producing small, simple molecules. Biologics are large, complex proteins manufactured using living cells. Ajovy is produced using recombinant DNA technology, meaning scientists program living cells to build the antibody protein, which is then purified and formulated for injection.
Ajovy specifically belongs to a class called monoclonal antibodies. These are lab-made proteins designed to lock onto one precise target in the body. In Ajovy’s case, the target is calcitonin gene-related peptide (CGRP), a molecule that plays a central role in triggering migraine pain and inflammation. By binding to CGRP, Ajovy prevents it from activating the pain signaling pathways that lead to migraine attacks.
Why the Biologic Classification Matters
Whether a drug is a biologic affects several things you’ll encounter as a patient. Biologics go through a different FDA approval process than standard drugs, and they can’t be replicated as easily. When a traditional drug loses patent protection, generic versions can be manufactured with identical chemical structures. With biologics, the best that can be produced is a “biosimilar,” a near-copy that must undergo its own clinical testing to prove it works comparably. No biosimilar for Ajovy is currently available.
The biologic classification also explains the cost. Ajovy’s wholesale acquisition cost was approximately $733 for a 30-day supply at the end of 2024. That price reflects the expensive, cell-based manufacturing process biologics require. Most patients rely on insurance coverage or manufacturer savings programs to offset this.
How Ajovy Is Used
Ajovy is approved for the preventive treatment of migraine in adults and in children ages 6 to 17 who weigh at least about 99 pounds. It’s not a treatment you take during a migraine. Instead, it works continuously in the background to reduce how many migraine days you experience each month.
One practical advantage of Ajovy over some other biologics is its flexible dosing schedule. You can choose between two options: a single 225 mg injection once a month, or three consecutive 225 mg injections (675 mg total) once every three months. Both are self-administered at home as subcutaneous shots, meaning you inject just under the skin using a prefilled syringe or autoinjector. The quarterly option is appealing if you prefer fewer injection days, though it does mean giving yourself three shots in one sitting.
Common Side Effects
Because Ajovy is injected rather than swallowed, the most frequent side effects are localized reactions at the injection site. In a long-term safety study, about 33% of patients experienced hardness at the injection site, 31% reported injection-site pain, and 26% had redness. These reactions are typically mild and resolve on their own.
Overall, adverse events leading patients to stop treatment occurred in only 3% to 5% of cases. The most common reasons for discontinuation were persistent injection-site redness, rash, swelling, or itching. Serious side effects were reported in 5% to 7% of patients across treatment groups, at similar rates regardless of dosing schedule.
Storage Requirements
Like most biologics, Ajovy needs refrigeration. You should store it at 36°F to 46°F in its original carton to protect it from light. If you need to travel or don’t have fridge access, Ajovy can stay at room temperature (up to 86°F) for a maximum of 7 days. After that window, any unused medication must be discarded. Once you take it out of the refrigerator, you cannot put it back in.
Before injecting, let the prefilled syringe or autoinjector sit at room temperature for about 30 minutes. Injecting cold medication can make the shot more uncomfortable.
How Ajovy Compares to Other CGRP Biologics
Ajovy isn’t the only biologic targeting CGRP for migraine prevention. It belongs to a group of monoclonal antibody treatments that all work by blocking CGRP activity, though they differ in their exact molecular targets and dosing schedules. Ajovy’s quarterly dosing option is a distinguishing feature, as some competitors require monthly injections only. All of the CGRP monoclonal antibodies share a similar side effect profile centered on injection-site reactions, and all carry the higher price tag associated with biologic manufacturing.